Scholarlink

Purpose&#xa0;of Review <p>A Ketogenic diet (KD; a diet comprised of 75% fat, 20% protein and 5% carbohydrates) has gained much popularity in recent years, especially regarding neurogliomas (or “gliomas”). This review critically assesses literature on the application of KD throughout the cancer continuum from a Medical Nutrition Therapy (MNT) perspective.</p> Recent Findings <p>2021 revised classification standards for Central Nervous System (CNS) tumors are available. Despite research on KD and CNS tumors increasing, the role and benefits of MNT to augment side effects of traditional treatment and KD throughout the cancer continuum remain unclear.</p> Summary <p>Glioma cancer survivors may benefit from a KD. It is a challenging, yet feasible non-pharmacological adjuvant approach. More research is needed regarding KD for prevention and post-treatment of glioma. Standard guidelines regarding macronutrient composition of KD for glioma are warranted. The need and benefits of nutritional guidance provided by a Registered Dietitian Nutritionist (RD or RDNs) during adherence to KD are understated.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Critical Review of Ketogenic Diet Throughout the Cancer Continuum for Neuroglioma: Insights from a Medical Nutrition Therapy (MNT) Perspective

  • 期刊论文

  • 发表日期：

    2025年1月30日

查看全文
  • Kristina D. Thomopoulos-Titomihelakis,
  • Hillary Sachs,
  • Rayna McCann,
  • Qianhui Zhang,
  • Sydney Kurnit,
  • Genesis Codoni De Juan,
  • Amanda Rushing

摘要

Purpose of Review

A Ketogenic diet (KD; a diet comprised of 75% fat, 20% protein and 5% carbohydrates) has gained much popularity in recent years, especially regarding neurogliomas (or “gliomas”). This review critically assesses literature on the application of KD throughout the cancer continuum from a Medical Nutrition Therapy (MNT) perspective.

Recent Findings

2021 revised classification standards for Central Nervous System (CNS) tumors are available. Despite research on KD and CNS tumors increasing, the role and benefits of MNT to augment side effects of traditional treatment and KD throughout the cancer continuum remain unclear.

Summary

Glioma cancer survivors may benefit from a KD. It is a challenging, yet feasible non-pharmacological adjuvant approach. More research is needed regarding KD for prevention and post-treatment of glioma. Standard guidelines regarding macronutrient composition of KD for glioma are warranted. The need and benefits of nutritional guidance provided by a Registered Dietitian Nutritionist (RD or RDNs) during adherence to KD are understated.